Werewolf Therapeutics, Inc.

NASDAQ:HOWL

Biotechnology

Healthcare
$1.03 +6.12%

+$0.06 today

Market cap
$50.06M
Beta
0.29
P/E (TTM)
-1.4
EPS (TTM)
-$0.71
52W Low $0.27High $1.83

Volume 1.85M

Average 5.09M

HOWL Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Werewolf Therapeutics, Inc.NASDAQ: HOWL

Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026

Accounts receivables outflow grows to $0

Q2 FY2026 accounts receivables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was $0.

Context

  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMJun 2026
$0-100.0% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Accounts Receivables vs competitors

How HOWL compares with its peers on the latest reported figures

  • HOWL's LTM Jun 2026 accounts receivables of $0 is the 5th largest of the 8 companies compared; the peer median is $0.
  • Its year-over-year change of -100.0% is the 2nd highest of 3, against a peer median of -333.6%.
  • Accounts receivables amounts to 0.0% of revenue for HOWL, versus a peer median of 22.2%.
HOWL Competitors Peer median
Accounts Receivables for HOWL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CUECue Biopharma, Inc.LTM Mar 2026$7.25M -617.9%—22.2%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$968.41K ——290.7%
INMBINmune Bio, Inc.LTM Mar 2026$646K -49.3%+1.9%—
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$12K ——0.5%
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$0 -100.0%—0.0%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$0 ———
OSTXOS Therapies IncorporatedLTM Mar 2026$0 ———
ACETAdicet Bio, Inc.LTM Mar 2026$0 ———
Peer median (excluding HOWL) $0-333.6%+1.9%22.2%

Competitors are the stored peer set for HOWL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(49.98M)(53.81M)(37.37M)(70.52M)(60.82M)
Depreciation & Amortization216K1.1M1.76M1.81M1.63M
Deferred Income Tax00000
Stock-Based Compensation4.1M7.4M8.01M8.83M6.25M
Change in Working Capital2.28M2.54M(5.89M)2.53M(8.21M)
Accounts Receivables0(6.93M)5.58M1.35M0
Inventory06.93M000
Accounts Payables1.01M(883K)(4.34M)3.46M(7.5M)
Other Working Capital1.27M3.42M(7.14M)(2.28M)(707K)
Other Non-Cash Items519K2.17M878K1.16M856K
Operating Cash Flow(42.88M)(40.6M)(32.61M)(56.19M)(60.29M)
Capital Expenditures(498K)(3.61M)(769K)(254K)0
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(498K)(3.61M)(769K)(254K)0
Debt Repayment0040M(10M)0
Common Stock Issued111.6M15.74M18.33M23.58M6.03M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(2.17M)166K100K(496K)0
Financing Cash Flow109.43M15.91M58.43M13.08M6.03M
Effect of Forex Changes00000
Net Change in Cash66.05M(28.3M)25.05M(43.36M)(54.26M)
Free Cash Flow(43.37M)(44.21M)(33.38M)(56.44M)(60.29M)

Werewolf Therapeutics, Inc.

NASDAQ:HOWL

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.